Mo. Attorney General sends prescription manufacturer Eli Lilly cease-and-desist over drug price policy
Missouri's Attorney General issues a cease-and-desist letter to drug manufacturer Eli Lilly over a contested pricing policy.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
The Missouri Attorney General issued a cease-and-desist letter to Eli Lilly, warning the pharmaceutical company to stop requiring data from hospitals seeking 340B drug discounts following a pricing dispute with MU Health Care. Concurrently, several hospitals filed a lawsuit against Eli Lilly alleging extortion regarding the drug discount program.
The story quieted without a definitive conclusion in the coverage regarding the final outcome of the cease-and-desist order or the litigation.
Epilogue added 15d ago, after coverage quieted.
The brief
According to these sources, the Missouri Attorney General has formally issued a cease-and-desist letter to Eli Lilly. The action targets the pharmaceutical company's requirement that hospitals submit specific data when seeking 340B drug discounts, a practice that has triggered an intense pricing dispute involving institutions such as MU Health Care. Simultaneously, reporting highlights broader legal challenges against the manufacturer.
The Boston Globe covers a lawsuit filed by MGH, Brigham, and other hospitals explicitly alleging extortion in connection with the drug discount program. Law360 frames these developments within a larger pattern of ongoing legal battles, identifying three critical cases to watch as the 340B program disputes continue to unfold across multiple jurisdictions and involve various healthcare providers alongside state officials. The context provided by the coverage roots these developments in the operational tensions surrounding the 340B drug pricing program, which requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations at significantly reduced prices.
The conflict escalated as Eli Lilly implemented data-sharing requirements that participating hospitals and state authorities are now aggressively challenging through both regulatory warnings and federal litigation, asserting that the manufacturer's conditions improperly restrict access to mandated discounts. As the situation develops, current coverage does not yet specify the full scope of Eli Lilly's formal response to the Missouri Attorney General's cease-and-desist letter or the immediate operational changes the company might implement. Observers and legal analysts are advised to monitor the progression of the hospital lawsuits detailed by The Boston Globe and the broader 340B litigation tracked by Law360 to see how courts evaluate the legality of the disputed data requirements and pricing policies.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (90% supported) Updated 19d ago.
Quick answers
Which company received a cease-and-desist letter from the Missouri Attorney General?
Prescription manufacturer Eli Lilly received the cease-and-desist letter.
What is the primary subject of the dispute involving Eli Lilly?
The dispute centers on the 340B drug discount program and Eli Lilly's requirements for data from hospitals seeking those discounts.
Which hospitals filed a lawsuit alleging extortion by Eli Lilly?
Coverage from The Boston Globe notes that MGH, Brigham, and other hospitals filed the lawsuit.
Coverage (6)
- 3 Cases To Watch In The 340B Battles Law360 · 22d ago
- Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discounts STAT · 22d ago
- MGH, Brigham, other hospitals sue Eli Lilly alleging ‘extortion’ in drug discount program The Boston Globe · 22d ago
- AG sends cease-and-desist letter to pharmaceutical company after pricing spat with MU Health Care ABC17NEWS · 22d ago
- Missouri Attorney General sends cease-and-desist letter to drug manufacturer KOMU 8 · 22d ago
- Mo. Attorney General sends prescription manufacturer Eli Lilly cease-and-desist over drug price policy KMOV · 22d ago
Topics
Related trends
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Seawolf Therapeutics launches with $100 million from Versant Ventures and Eli Lilly to develop non-viral gene therapies targeting obesity, muscle loss, and osteoporosis.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.
The present state of US financial enforcement
SEC enforcement against public companies fell to a record low under Chair Paul Atkins in fiscal year 2026.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
Eli Lilly's weight-loss pill Foundayo meets its main goal in a late-stage trial by easing sleep apnea.
Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.